Citations

Showing 10 of 108094 citations.

Considerations in caseous calcification of the mitral annulus: a case report
Naser, Jwan A. , Hemu, Mohamad , Pellikka, Patricia A. , Hemu, Mohamad R, Pellikka, Patricia A , Naser, Jwan A

Mayo Clinic

European Heart Journal - Case Reports | November 14, 2022 | Volume: 6 | Issue: 11 | Pages: No page available

10.1093/ehjcr/ytac442 | PMID 36415686 Get It

Abstract Background Caseous calcification of the mitral annulus is an extremely rare variant of mitral annulus calcification occurring in <1% of cases. The degeneration of caseous masses could act as a source of embolic strokes and a nidus for infective endocarditis (IE). Case summary A man in his sixties presented with transient left arm weakness. His history was pertinent for bioprosthetic aortic valve replacement secondary to endocarditis and recent pneumococcal pneumonia complicated by empyema and bacteraemia. He was still on intravenous antibiotics when he presented. Evaluation including magnetic resonance imaging of the brain, transoesophageal echocardiography, and computed tomography (CT) of the chest revealed multifocal embolic strokes, degenerative bioprosthetic aortic valve dysfunction, mitral annular calcification with mobile calcific masses, and persistent empyema. 18F-fluorodeoxyglucose–positron emission tomography–CT showed indeterminate activity across a portion of the posterior mitral leaflet and no activity on the bioprosthetic aortic valve. The patient was deemed high risk for surgery and was treated with 6-week course of antibiotics both for the empyema and the possible IE of the native mitral valve. Repeat echocardiography 40 days later showed stable mitral masses. At 4 months of follow up, the patient had no evidence of recurrent clinical strokes. Discussion Caseous calcification of the mitral annulus is a rare but an increasingly recognized predisposing factor for embolic strokes and IE. Treatment ideally involves surgical resection of the calcified masses in such cases.
Examining age of onset phenotype in the spectrum of mood disorders
Núñez, Nicolás A. , Miola, Alessandro , Frye, Mark A.

Mayo Clinic

International Clinical Psychopharmacology | November 14, 2022 | Volume: 38 | Issue: 1 | Pages: 66-67

10.1097/yic.0000000000000445 | PMID 36373788 Get It

Memorial notice: William L. Nichols, MD
Pruthi, Rajiv K. , Smock, Kristi J. , Hayward, Catherine P.M.

Mayo Clinic

International Journal of Laboratory Hematology | November 14, 2022 | Volume: 45 | Issue: 2 | Pages: 139-140

10.1111/ijlh.13994 Get It

Early diagnosis of hepatic inflammation in Japanese nonalcoholic fatty liver disease patients using 3D MR elastography
Komiyama, Yasuyuki , Maekawa, Shinya , Osawa, Leona , Nakakuki, Natsuko, Muraoka, Masaru , Suzuki, Yuichiro , Sato, Mitsuaki, Takano, Shinichi , Fukasawa, Mitsuharu , Yamaguchi, Tatsuya , Enomoto, Nobuyuki, Maekawa, Shinya , Yin, Meng , Motosugi, Utaroh , Takada, Hitomi , Onishi, Hiroshi , Yin, Meng

Mayo Clinic

Hepatology Research | November 14, 2022 | Volume: 53 | Issue: 3 | Pages: 208-218

10.1111/hepr.13858 | PMID 36372908 Get It

AbstractBackgroundThe damping ratio (DR) and the loss modulus (G″) obtained by 3D MR elastography complex modulus analysis has been reported recently to reflect early intrahepatic inflammation, and is expected to be a noninvasive biomarker of inflammation in nonalcoholic fatty liver disease (NAFLD). However, the role of the DR and the G″ in Japanese NAFLD patients remains unclear.MethodsWe enrolled 39 Japanese patients with NAFLD who underwent liver biopsy and 3D MR elastography within 1 month and analyzed the association between DR, G″, and histological activity.ResultsRegarding DR, no evident correlation was observed between the DR and histological activity (p = 0.14) when patients with all fibrosis stages were included. However, when patients were restricted up to stage F2 fibrosis, the association of the DR and inflammation became significant, the DR increasing with the degree of activity (p = 0.02). Among the constituents of fibrosis activity, ballooning correlated with the DR (p < 0.01) while lobular inflammation did not. Regarding G″, it was correlated with histological activity (p < 0.01), ballooning (p < 0.01), and lobular inflammation (p < 0.01) in patients with all fibrosis stages and in patients up to F2 fibrosis (p = 0.03 for activity and p = 0.04 for ballooning). The best cutoff value of DR for hepatitis activity in patients within the F2 stage was 0.094 (area under the receiver operating characteristic curve 0.775, 95% CI: 0.529–1.000) and G″ was 0.402 (area under the receiver operating characteristic curve 0.825, 95% CI: 0.628–1.000).ConclusionsThe DR and G″ reflected the histological activity in Japanese patients with NAFLD during the early stage, indicating these values for noninvasive diagnosis of inflammation in Japanese patients with NAFLD.
Sexual Health after a Breast Cancer Diagnosis: Addressing a Forgotten Aspect of Survivorship
Vegunta, Suneela , Kuhle, Carol L. , Vencill, Jennifer A. , Lucas, Pauline , Mussallem, Dawn M. , Lucas, Pauline H.

Mayo Clinic

Journal of Clinical Medicine | November 14, 2022 | Volume: 11 | Issue: 22 | Pages: 6723

10.3390/jcm11226723 | PMID 36431200 Get It

Breast cancer is the most common cancer in women. The life expectancy after a breast cancer diagnosis is improving steadily, leaving many more persons with the long-term consequences of treatment. Sexual problems are a common concern for breast cancer survivors yet remain overlooked in both the clinical setting and the research literature. Factors that contribute to sexual health concerns in breast cancer survivors are biopsychosocial, as are the barriers to addressing and treating these health concerns. Sexual health needs and treatment may vary by anatomy and gender. Multidisciplinary management may comprise lifestyle modifications, medications, sexual health aids such as vibrators, counseling, and referrals to pelvic health physical therapy and specialty care. In this article, we review the contributing factors, screening, and management of sexual difficulties in cisgender female breast cancer survivors. More information is needed to better address the sexual health of breast cancer survivors whose sexual/gender identity differs from that of cisgender women.
Evaluation and Catheter Ablation of Ventricular Arrhythmias in Cardiac Sarcoidosis
Ezzeddine, Fatima M. , Tan, Nicholas Y. , Siontis, Konstantinos C. , Ezzeddine, Fatima

Mayo Clinic

Journal of Clinical Medicine | November 14, 2022 | Volume: 11 | Issue: 22 | Pages: 6718

10.3390/jcm11226718 | PMID 36431195 Get It

Ventricular arrhythmias are a common clinical manifestation in patients with cardiac sarcoidosis (CS) and other arrhythmogenic inflammatory cardiomyopathies (AIC). The management of sustained ventricular arrhythmias in these patients presents unique challenges. Current therapies include immunosuppressive, antiarrhythmic agents, and catheter ablation. Significant progress has been made in deciphering the importance of patient selection for ablation, systematic preablation evaluation, and optimal ablation timing, as well as ablation approaches and techniques. In this overview, we discuss the evaluation and management of ventricular arrhythmias in patients with CS, focusing on catheter ablation, which has evolved into an effective approach in reducing the burden of ventricular arrhythmias in these patients in the context of multifaceted treatment along with medical therapies.
CTNI-23. PRELIMINARY SAFETY AND PHARMACOKINETICS DATA FOR A PHASE 1B TRIAL OF TELAGLENASTAT IN COMBINATION WITH RADIATION THERAPY AND TEMOZOLOMIDE IN PATIENTS WITH IDH-MUTANT GRADE 2/3 ASTROCYTOMA (NCI-10218)
Kizilbash, Sani H. , Sahebjam, Solmaz , Jaeckle, Kurt A. , Welch, Mary , Kong, Xiao–Tang , Holdhoff, Matthias , Lammers, Anita, Remick, Adam, Allred, Jacob B., McBrayer, Samuel K. , Kunos, Charles A., Adjei, Alex A. , Kizilbash, Sani H , Piccioni, David Eric , Villano, John L. , Reid, Joel M. , Port, John D. , Lanza, Ian R. , Shapiro, Geoffrey I.

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii75-vii75

10.1093/neuonc/noac209.288 Get It

Abstract IDH mutant gliomas depend on glutaminase for glutamate/glutathione generation from glutamine because R-2-hydroxyglutarate inhibits branched chain amino acid transaminase mediated glutamate biosynthesis. Telaglenastat (CB-839 HCl) is a potent glutaminase-1 specific inhibitor which depletes tumor glutamate in orthotopic IDH mutant glioma PDX models and extends survival in these orthotopic models when added to radiation/temozolomide. NCI-10218 (NCT03528642) is a phase I clinical trial investigating the safety and tolerability of telaglenastat administered orally concurrently with standard doses of radiation (50.4 Gy, grade 2; 59.4 Gy, grade 3) and temozolomide (75 mg/m2 orally daily) in patients (age 16+) with previously untreated IDH mutant grade 2/3 astrocytoma. Telaglenastat dose was escalated in cohorts (400-800 mg twice daily) based on a standard 3 + 3 design to determine the recommended phase 2 dose (RP2D). Toxicities were graded per CTCAE v5.0. An expansion cohort additionally incorporated a seven-day run-in of telaglenastat monotherapy at RP2D prior to radiation to evaluate the pharmacodynamic impact of telaglenastat on plasma and tumor metabolites. 23 patients with IDH mutant astrocytoma (WHO grade 2, n = 5; WHO grade 3, n = 18) were accrued between December 2018 and January 2022 (Dose Escalation: 16; Dose Expansion: 7). Median age was 32 years (range 23-69 years). 61% were male and 70% were ECOG 0. No dose-limiting toxicities were observed. Grade 3/4 adverse events (independent of attribution) included: lymphopenia (3), neutropenia (2), leukocytosis (2), alanine transaminase elevation (2), thrombocytopenia (1), leukopenia (1), maculopapular rash (1), hyperglycemia (1), hyponatremia (1). The RP2D of concurrent telaglenastat was defined as 800 mg twice daily. Following peak absorption on Day 15 at RP2D, the mean (%CV) terminal elimination half-life in the plasma was 4.2 (53.5%) hours (range 2.1-7.1 hours). The Cmax, Tmax, oral clearance, and AUC were 1496 ng/mL, 4.0 hr, 93.6 L/hr/m2, and 7430 ng/mL*hr, respectively.
CTNI-16. NRG-RTOG 9802 OBSERVATION ARM - LONG TERM RESULT
Polley, Mei‐Yin C. , Shaw, Edward , Buckner, Jan C. , Barger, Geoffrey, Coons, Stephen Joel , Ricci, Peter E. , Gilbert, Mark, Brown, Paul D. , Stelzer, K. , Rogers, Leland , Schultz, Christopher J. , Howard, Steven , Fisher, Barbara, Haddock, Michael G. , Won, Minhee , IWAMOTO, FABIO MASSAITI , Coons, Stephen, Suh, John H. , Kim, Michelle H. , Huang, Jiayi , Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii73-vii73

10.1093/neuonc/noac209.282 Get It

Abstract BACKGROUND Radiation Therapy Oncology Group 9802 was a phase III trial for patients with centrally confirmed LGG (WHO grade II). Participants ³ 40 years or those with neurosurgeon defined less than gross total resection (GTR) were randomized to radiotherapy (RT) +/- PCV. In a separate cohort, adults age &lt; 40 years with neurosurgeon defined GTR were observed by MRI every 6 months without adjuvant therapy. At last report, outcome for the observation cohort was immature with median follow-up of only 4.4 years. Here, we present mature outcomes for the observation arm. METHODS Eligible adults (as above) were observed by MRI every 6 months. OS and PFS were estimated by Kaplan-Meier method and estimated hazard ratios to characterize the prognostic variables. RESULTS There were 111 eligible patients (median age 30; median KPS = 100). Median follow-up was 16.1 years with 71 (64%) alive at the last follow-up. 79 patients (71%) had progressed with median PFS of 6.9 years. 5, 10, and 15 year-PFS and OS rates were 54%, 39%, 28% and 94%, 77%, and 65%. 1p19q status was codeleted in 32%, IDH1/2 mutant in 78% and MGMT promoter methylated in 39% of tested cases. Multivariate Cox analyses showed that preoperative tumor size ³ 4 cm (HR = 2.43 for PFS, p = 0.001; HR = 2.58 for death, p = 0.016) and residual disease on imaging ³ 1 cm (HR = 2.97 for PFS, P &lt; 0.001; HR = 2.02 for death, p = 0.05) were associated with worse outcomes. Analyses based on molecular results will be presented. CONCLUSION A subset of low-grade gliomas can be observed after the initial resection based on younger age, smaller tumor size, and no residual disease on neuroimaging. This can likely be further refined by prognostic molecular markers. Patients with the most favorable prognostic factors can avoid or delay the acute and long-term side effects of RT and chemotherapy for several years.
Quantifying the phenome‐wide disease burden of obesity using electronic health records and genomics
Robinson, Jamie R. , Carroll, Robert J. , Bastarache, Lisa , Pirruccello, James P. , Mou, Zongyang , Wei, Wei‐Qi, Mentch, Frank , Crane, Paul K. , Hebbring, Scott J. , Crosslin, David R. , Rosenthal, Elisabeth A. , Stanaway, Ian B. , Petukhova, Lynn , Namjou‐Khales, Bahram, Zhang, Ge , Safarova, Mayya S., Walton, Nephi , Still, Christopher D. , Böttinger, Erwin P. , Loos, Ruth J. F. , Murphy, Shawn N. , Jarvik, Gail P. , Larson, Eric B. , Roden, Dan M. , Denny, Joshua C. , Safarova, Maya , Denny, Joshua C , Jarvik, Gail P , Loos, Ruth J F , Chen, Qingxia , Connolly, John J. , Gordon, Adam S., Hayes, M. Geoffrey , Wei, Wei , Jackson, Gretchen Purcell , Abumrad, Naji N. , Kullo, Iftikhar J. , Weng, Chunhua , Roden, Dan M. , Khera, Amit V.

Mayo Clinic

Obesity | November 14, 2022 | Volume: 30 | Issue: 12 | Pages: 2477-2488

10.1002/oby.23561 | PMID 36372681 Get It

AbstractObjectiveHigh BMI is associated with many comorbidities and mortality. This study aimed to elucidate the overall clinical risk of obesity using a genome‐ and phenome‐wide approach.MethodsThis study performed a phenome‐wide association study of BMI using a clinical cohort of 736,726 adults. This was followed by genetic association studies using two separate cohorts: one consisting of 65,174 adults in the Electronic Medical Records and Genomics (eMERGE) Network and another with 405,432 participants in the UK Biobank.ResultsClass 3 obesity was associated with 433 phenotypes, representing 59.3% of all billing codes in individuals with severe obesity. A genome‐wide polygenic risk score for BMI, accounting for 7.5% of variance in BMI, was associated with 296 clinical diseases, including strong associations with type 2 diabetes, sleep apnea, hypertension, and chronic liver disease. In all three cohorts, 199 phenotypes were associated with class 3 obesity and polygenic risk for obesity, including novel associations such as increased risk of renal failure, venous insufficiency, and gastroesophageal reflux.ConclusionsThis combined genomic and phenomic systematic approach demonstrated that obesity has a strong genetic predisposition and is associated with a considerable burden of disease across all disease classes.
Palliative Care Utilization Among Hospitalized Patients With Common Chronic Conditions in the United States
Rashid, Muhammad , Warriach, Haider J, Lawson, Claire , Spall, Harriette G.C. Van , Khan, M Shahzab, Mohamed, Mohamed O. , Shoaib, Ahmad , Diwan, Masroor, Gosh, Raktim, Bhatt, Deepak L. , Mamas, Mamas A. , Van Spall, Harriette G C , Mamas, Mamas , Bhatt, Deepak L , Mohamed, Mohamed O , Alkhouli, Mohamad , Khan, Safi U. , Khan, Muhammad Zia

Mayo Clinic

Journal of Palliative Care | November 14, 2022 | Volume: 41 | Issue: 1 | Pages: 28-40

10.1177/08258597221136733 | PMID 36373247 Get It

Objective: Limited data exist around the receipt of palliative care (PC) in patients hospitalized with common chronic conditions. We studied the independent predictors, temporal trends in rates of PC utilization in patients hospitalized with acute exacerbation of common chronic diseases. Methods: Population-based cohort study of all hospitalizations with an acute exacerbation of heart disease (HD), cerebrovascular accident (CVA), cancer (CA), and chronic lower respiratory disease (CLRD). Patients aged ≥18 years or older between January 1, 2004, and December 31, 2017, referred for inpatient PC were extracted from the National Inpatient Sample. Poisson regression analyses were used to estimate temporal trends. Results: Between 2004 and 2017, of 91,877,531 hospitalizations, 55.2%, 13.9%, 17.2%, and 13.8% hospitalizations were related to HD, CVA, CA, and CLRD, respectively. There was a temporal increase in the uptake of PC across all disease groups. Age-adjusted estimated rates of PC per 100,000 hospitalizations/year were highest for CA (2308 (95% CI 2249–2366) to 10,794 (95% CI 10,652–10,936)), whereas the CLRD cohort had the lowest rates of PC referrals (255 (95% CI 231–278) to 1882 (95% CI 1821–1943)) between 2004 and 2017, respectively. In the subgroup analysis of patients who died during hospitalization, the CVA group had the highest uptake of PC per 100,000 hospitalizations/year (4979 (95% CI 4918–5040)) followed by CA (4241 (95% CI 4189–4292)), HD (3250 (95% CI 3211–3289)) and CLRD (3248 (95% CI 3162–3405)). Conclusion: PC service utilization is increasing but remains disparate, particularly in patients that die during hospital admission from common chronic conditions. These findings highlight the need to develop a multidisciplinary, patient-centered approach to improve access to PC services in these patients.